Search
Close this search box.

Small biotechs reveal reliance on Chinese CDMOs

ARTICLE | Politics, Policy & Law

SEC filings disclose potential negative impacts of Biosecure Act 

By Steve Usdin, Washington Editor

March 29, 2024 10:11 PM UTC

While almost every major pharmaceutical company would be directly affected if Congress enacts legislation restricting access to the services of Chinese contract research and manufacturing companies, the biggest impacts are likely to be felt by small biotechs.

Virtually every large pharma company works with a Chinese CDMO, but none are as reliant on companies such as WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) and WuXi Biologics Inc. (HKEX:2269) as companies that lack their own manufacturing capabilities.